ADCT ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company’s confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main efficacy bar, but the FDA has flagged serious safety concerns about the combination that could complicate its path to a fuller […] | ||
 ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript FDA raised safety concerns about ZYNLONTA combination therapy in LOTIS-5 trial. | ||
 ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook The central fair value estimate for ADC Therapeutics has been cut from US$5.00 to about US$3.33, which marks a sizeable reset in modeled upside for the stock. Analysts are linking these lower targets to mixed LOTIS-5 outcomes, a more cautious view on Zynlonta’s growth potential, and a wider debate on how much LOTIS-7 can offset current concerns. As you read on, you will see how this evolving narrative might shape expectations and what to watch next if you follow ADC Therapeutics. Analyst... | ||
 ADC Therapeutics S.A. Q2 2026 Earnings Call Summary Moby summary of ADC Therapeutics S.A.'s Q2 2026 earnings call | ||
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... ADC Therapeutics reports stable Zynlonta sales and cost savings, but faces FDA concerns over LOTUS-5 that cloud the path to full approval. | ||
 ADC Therapeutics Q2 Earnings Call Highlights ADC Therapeutics (NYSE:ADCT) reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment’s commercial performance remained broadly consistent with recent quarters. The company also said it is rea | ||
 ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Alkermes (ALKS) Reports Break-Even Earnings for Q2 Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 The Cancer Therapy Strategy VERAXA Is Betting the Company On By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge. | ||